Chemists at the University of California, Davis did something that borders on the molecular equivalent of pulling off a magic trick. They moved two atoms within the intricate structure of LSD—a drug ...

MindMed’s MNMD Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed. “We have seen a meaningful acceleration in ...

Psychedelics biotech BetterLife Pharma Inc. BETRF is fast-tracking its U.S. patent application covering the composition of matter, treatment uses and a novel production method of non-hallucinogenic ...

The work was led by David E. Olson, director of the Institute for Psychedelics and Neurotherapeutics at the University of California, Davis. Scientists in Olson’s lab and at Delix Therapeutics, a ...

Researchers at UC Davis have fiddled with LSD at the atomic level and may have unlocked a potential game-changing treatment for schizophrenia. The new compound, known as JRT, might be able to repair ...